Spila A, Roselli M, Cosimelli M, Ferroni P, Cavaliere F, Arcuri R, Tedesco M, Carlini S, D'Alessandro R, Perri P, Casciani C U, Greiner J W, Schlom J, Guadagni F
Regina Elena Cancer Institute, Rome, Italy.
Anticancer Res. 1996 Jul-Aug;16(4B):2241-7.
CA 72-4 is a high molecular weight, pancarcinoma human tumor mucin which may play an important role in the identification (i.e., staging) and clinical management of patients with gastric carcinoma. In the present study of 242 patients with primary or recurrent gastric cancer, a higher percentage of these patients had measurable serum CA 72-4 levels when compared with either CA 19.9 or CEA. Moreover, the presence of positive serum CA 72-4 levels correlated with the presence of lymph node involvement and with the identification of patients with a poor prognosis due to the presence of an advanced stage of gastric cancer. Post-operative monitoring of serum CA 72-4 revealed that the disappearance of CA 72-4 often indicated curative surgery which correlated with a longer disease-free interval. Additional clinical studies are needed to better evaluate the role of CA 72-4 as a serum marker for human gastric carcinoma. Concomitant studies should also focus on what role CA 72-4 may play in the initiation and/or progression of the gastric carcinoma phenotype.
CA 72-4是一种高分子量的泛癌人类肿瘤黏蛋白，可能在胃癌患者的识别（即分期）和临床管理中发挥重要作用。在本项针对242例原发性或复发性胃癌患者的研究中，与CA 19.9或CEA相比，这些患者中可检测到血清CA 72-4水平的比例更高。此外，血清CA 72-4水平呈阳性与淋巴结受累情况相关，也与因胃癌处于晚期而预后不良的患者识别相关。血清CA 72-4的术后监测显示，CA 72-4消失往往表明手术治愈，这与更长的无病间期相关。需要进行更多临床研究，以更好地评估CA 72-4作为人类胃癌血清标志物的作用。相关研究还应关注CA 72-4在胃癌表型的发生和/或进展中可能发挥的作用。
